Heart Disease News and Research

Latest Heart Disease News and Research

Carrots and plums for better looks!

Researchers at St Andrews and Bristol universities have found that carrots and plums could make one more attractive in just two months. They found that these fruits and vegetables contain pigments called carotenoids that color the skin within two months making a person more attractive and healthy.

9 Jan 2011

Vaccines for alcoholism and cocaine addiction coming soon

In a latest development, researchers from Chile have come up with a vaccine to cure alcoholics. It will help them kick the habit by creating a sensation of a terrible hangover after just a few drinks. The mechanism by which this vaccine acts is by neutralizing a group of enzymes that help the body to break down alcohol. When the enzymes aldehyde dehydrogenase is disabled the body accumulates the alcohol to create the hangovers after just a few drinks.

9 Jan 2011

Gigantism gene inherited by hundreds: Study

A gene that predicted gigantism in humans was identified in the DNA of the 18th-century man known as the Irish Giant, who was more than 7 feet 7 inches tall. Copies of the same mutation have been found in patients today who suffer from excessive growth, and scientists have concluded they all inherited the gene from a common ancestor.

9 Jan 2011

Sniffing women's tears reduces sexual arousal in men

Emotional crying is a universal, uniquely human behavior. When we cry, we clearly send all sorts of emotional signals. In a paper published online today in Science Express, scientists at the Weizmann Institute have demonstrated that some of these signals are chemically encoded in the tears themselves. Specifically, they found that merely sniffing a woman's tears - even when the crying woman is not present -- reduces sexual arousal in men.

7 Jan 2011

Underwriters exercise over-allotment option in Amarin ADS public offering

Amarin Corporation plc, a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today announced that, in connection with its previously announced underwritten public offering of American Depositary Shares ("ADSs"), the underwriters of the offering have exercised in full their option to purchase up to an aggregate of 1,800,000 additional ADSs to cover over-allotments.

7 Jan 2011

Critical Diagnostics' high sensitivity Presage ST2 Assay receives CE Mark approval

Critical Diagnostics announced today that it has received CE (Conformité Européenne) Mark for its high sensitivity Presage ST2 Assay and is commencing commercialization in Europe. The product is indicated for use as an aid in risk stratification of patients with heart failure or acute coronary syndrome. This regulatory milestone marks the first time that an assay has become commercially available for the clinical measurement of the biomarker soluble ST2.

7 Jan 2011

Research roundup: Accountable Care Organizations; Electronic health records; Medicaid and deficit reductions

Health Affairs: Accountable Care Organizations: Making Them Work - The January issue of the journal features several articles examining initiatives underway that could help form ACOs, such as Blue Cross Blue Shield of Massachusetts' "Alternative Quality Contract,"a modified global payment model in which annual payments to medical groups are linked to a per member per month budget.

7 Jan 2011

FDA approved KOMBIGLYZE XR for type 2 diabetes mellitus now available in pharmacies

Bristol-Myers Squibb Company, and AstraZeneca today announced that KOMBIGLYZE™ XR (saxagliptin and metformin HCl extended-release), approved by the U.S. Food and Drug Administration (FDA) on November 5, 2010, is now available by prescription in pharmacies across the United States.

7 Jan 2011

Sucampo, Takeda initiate dosing in third lubiprostone phase 3 trial for opioid-induced bowel dysfunction

Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals North America, Inc. today announced the dosing of the first patient in the third phase 3 clinical trial of lubiprostone for the treatment of opioid-induced bowel dysfunction (OBD) in subjects with chronic, non-cancer pain, excluding those taking methadone. The primary endpoint is an overall responder rate based on the change from baseline in the reported frequency of spontaneous bowel movements (SBMs).

7 Jan 2011

BIND Biosciences commences BIND-014 Phase 1 clinical trial in cancer

BIND Biosciences announced today that it has initiated a Phase 1 clinical trial to assess the safety, tolerability and pharmacokinetic profile of BIND-014 in cancer patients. BIND-014, the first product candidate to enter clinical evaluation from BIND's broad proprietary Medicinal Nanoengineering platform, is a targeted polymeric nanoparticle containing the cytotoxic agent, docetaxel.

7 Jan 2011

BG Medicine enters agreement to develop galectin-3 test for Siemens' automated immunoassay platforms

BG Medicine, Inc. announced today that it has entered into an agreement with Siemens Healthcare Diagnostics Inc., a division of Siemens Healthcare, one of the world's largest suppliers of clinical diagnostics to the healthcare industry, for the development and commercialization of a galectin-3 test for Siemens' automated immunoassay platforms for clinical laboratories.

7 Jan 2011

IDSA releases MRSA treatment guidelines

Physicians now have help in their battle against methicillin resistant Staphylococcus aureus (MRSA), a potentially deadly infection that initially was limited to hospitals and health care facilities but has become a growing problem in healthy children and adults. The Infectious Diseases Society of America (IDSA) has released its first guidelines for the treatment of increasingly common MRSA infections.

7 Jan 2011

Cells that give rise to neurons maintain high levels of ROS

For years, the majority of research on reactive oxygen species (ROS) - ions or very small molecules that include free radicals - has focused on how they damage cell structure and their potential link to stroke, cardiovascular disease and other illnesses.

7 Jan 2011

Regular blood test shows pre-diabetes risk factors, reduces treatment costs

A simpler form of testing individuals with risk factors for diabetes could improve diabetes prevention efforts by substantially increasing the number of individuals who complete testing and learn whether or not they are likely to develop diabetes.

7 Jan 2011

Athersys completes patient enrollment in MultiStem Phase I study for leukemia

Athersys, Inc. today announced that it has completed patient enrollment of the single dose arm of a clinical study involving administration of MultiStem to patients being treated for leukemia or other blood born cancers.

7 Jan 2011

Poll shows strong support as Smoke-Free Kentucky Campaign launches today

Kentucky health advocates today released a new poll showing 59% of Kentucky voters support passing a law to make all restaurants, bars and other workplaces smoke-free. The release is part of the launch of Smoke-Free Kentucky's campaign to ensure that all Kentuckians have the right to breathe clean, smoke-free air in public places and at work.

7 Jan 2011

Study: Tβ4 can protect endothelial progenitor cells

RegeneRx Biopharmaceuticals, reported that a team of cardiovascular researchers in China have shown that Tβ4 can protect endothelial progenitor cells derived from the blood of healthy human volunteers.

7 Jan 2011

Esperion Therapeutics commences ETC-1002 Phase 2 clinical study for cardio-metabolic diseases

Esperion Therapeutics, a privately held biotechnology company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced that it has initiated a Phase 2 clinical study for ETC-1002, the company's lead product candidate.

7 Jan 2011

Positive topline results from RDEA594 Phase 2b study in patients with gout, allopurinol

Ardea Biosciences, Inc. announced positive, preliminary, top-line results from its Phase 2b study of RDEA594 in combination with the current standard of care for the treatment of gout, allopurinol.

7 Jan 2011

Isis Pharmaceuticals announces addition of two new drugs to development pipeline

Isis Pharmaceuticals, announced today that it has added two new drugs to its development pipeline, ISIS-FGFR4Rx and ISIS-STAT3Rx.

7 Jan 2011

Heart Disease News and Research

Latest Heart Disease News and Research

Carrots and plums for better looks!

Vaccines for alcoholism and cocaine addiction coming soon

Gigantism gene inherited by hundreds: Study

Sniffing women's tears reduces sexual arousal in men

Underwriters exercise over-allotment option in Amarin ADS public offering

Critical Diagnostics' high sensitivity Presage ST2 Assay receives CE Mark approval

Research roundup: Accountable Care Organizations; Electronic health records; Medicaid and deficit reductions

FDA approved KOMBIGLYZE XR for type 2 diabetes mellitus now available in pharmacies

Sucampo, Takeda initiate dosing in third lubiprostone phase 3 trial for opioid-induced bowel dysfunction

BIND Biosciences commences BIND-014 Phase 1 clinical trial in cancer

BG Medicine enters agreement to develop galectin-3 test for Siemens' automated immunoassay platforms

IDSA releases MRSA treatment guidelines

Cells that give rise to neurons maintain high levels of ROS

Regular blood test shows pre-diabetes risk factors, reduces treatment costs

Athersys completes patient enrollment in MultiStem Phase I study for leukemia

Poll shows strong support as Smoke-Free Kentucky Campaign launches today

Study: Tβ4 can protect endothelial progenitor cells

Esperion Therapeutics commences ETC-1002 Phase 2 clinical study for cardio-metabolic diseases

Positive topline results from RDEA594 Phase 2b study in patients with gout, allopurinol

Isis Pharmaceuticals announces addition of two new drugs to development pipeline

Innovation in neuroscience drug discovery - eBook eBook

How can super-resolution technology help study neurotransmission?

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Heart Disease News and Research

Latest Heart Disease News and Research

Innovation in neuroscience drug discovery - eBook eBook

How can super-resolution technology help study neurotransmission?

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Newsletters you may be interested in